Gerresheimer has successfully completed the acquisition of Blitz LuxCo Sarl, the holding company Bormioli Pharma Group, announced in May 2024.
Bormioli Pharma has a portfolio of glass and plastic pharmaceutical primary packaging, as well as closure solutions, accessories and dosing systems that are complementary to those of Gerresheimer. With this acquisition, Gerresheimer strengthens its European presence with additional production sites and reinforces its market position as a leading full-service provider and global partner for the pharmaceutical and biotechnology industries.
Gerresheimer expects the acquisition to be accretive to the Group's adjusted EBITDA margin and adjusted EPS from the first year onwards through synergies. On 26 February 2025, Gerresheimer will publish a new outlook for the combined company together with the results for the 2024 financial year.
“Following the successful completion of the acquisition, we can now focus on the integration of Bormioli Pharma into the Gerresheimer Group,” explains Dietmar Siemssen, CEO of Gerresheimer AG. “We are convinced that our customers will benefit from the expanded product portfolio and the new integrated systems and solutions.”
In 2023, Bormioli Pharma generated sales of around €371 million and an adjusted EBITDA margin of around 22%. The company manufactures glass and plastic pharmaceutical primary packaging as well as closure solutions, accessories and dosing systems. In the plastics segment, Bormioli Pharma is one of the leading suppliers of pharmaceutical plastic systems and solutions. In glass, it has an attractive portfolio of primary packaging for parenteral products and other pharmaceutical products.
Bormioli Pharma will become part of the Gerresheimer Group and has been fully consolidated retroactively from 1 December 2024, the start date of Gerresheimer's new financial year 2025. On 26 February 2025, Gerresheimer will therefore publish new forecasts for 2024 and new medium-term forecasts for the merged company together with the results for the 2025 financial year.
